IVA - Inventiva - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

145.3M

Cash

27.34M

Avg Qtr Burn

-20.4M

Short % of Float

0.89%

Insider Ownership

0.00%

Institutional Own.

9.25%

Qtr Updated

12/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lanifibranor (Pan-PPAR) Details Liver disease, Non-alcoholic steatohepatitis , Fatty liver disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lanifibranor + empagliflozin Details Liver disease, Non-alcoholic steatohepatitis , Fatty liver disease, Type 2 diabetes	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cedirogant (ABBV-157) (60RORy) Details Psoriasis, Kidney cancer, Carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Odiparcil (GAG) Details Rare diseases, Rare genetic disease, Mucopolysaccharidoses, Mucopolysaccharidosis type IV, Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.